Drawing on decades of experience in quality and regulatory leadership, this discussion explores what drives successful remediation programmes in the Medtech industry. From FDA warning letters and product recalls to proactive internal reviews, remediation is framed as a business-critical challenge rather than simply a compliance exercise.
Key themes include the importance of leadership sponsorship, clear scope definition, risk-based prioritisation, and balancing speed with thorough corrective action. Most importantly, effective remediation is viewed as an investment in long-term quality culture and operational resilience. Trinzo supports organisations in planning and delivering remediation programmes that withstand regulatory scrutiny and strengthen the business.